Cell Free DNA Analysis and Circulating Tumor Cell Characterization in Metastatic Breast Cancer


About this study

The objective of this study is to provide preliminary data to support the development of selected technologies for the efficient and reliable analyses of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in the setting of metastatic breast cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • age 18 years or older
  • histologic evidence of breast cancer with known hormone receptor and HER2 status
  • initiation of new systemic therapy for progressive metastatic disease or unresectable locally recurrent disease within four weeks of the blood draw
  • an understanding of the protocol and its requirements, risks, and discomforts
  • the ability and willingness to sign an informed consent
  • FFPE tumor tissue

Exclusion Criteria: 

  • pregnancy or lactation (for females)
  • inability on the part of the patient to understand the informed consent or be compliant with the protocol

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

George Vasmatzis, Ph.D.

Closed for enrollment

Contact information:

Center for Individualized Medicine


More information


Publications are currently not available

Mayo Clinic Footer